Results suggest that a shift in the distribution of tau, particularly neuronal tau, within the progressive supranuclear palsy network of regions is driving different clinical presentations in progressive supranuclear palsy. The gene discussed is MAPT; the disease is Classical progressive supranuclear palsy.